LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report) shares gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $15.15, but opened at $14.00. LogicBio Therapeutics shares last traded at $14.29, with a volume of 2,965 shares.
The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.25). The firm had revenue of $32.20 million during the quarter, compared to analyst estimates of $23.31 million.
LogicBio Therapeutics Stock Performance
The firm’s 50-day moving average price is $14.79 and its 200-day moving average price is $10.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.87 and a quick ratio of 1.24. The stock has a market cap of $657.37 million, a P/E ratio of -19.69 and a beta of 2.11.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.
LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.
See Also
- Five stocks we like better than LogicBio Therapeutics
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
